News
GlobalData on MSN11h
Arrowhead sells China hypertriglyceridemia candidate rights to SanofiArrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights ...
Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...
Zacks Investment Research on MSN5h
Sarepta to Report Q2 Earnings: What's in Store for the Stock?We expect Sarepta Therapeutics SRPT to report second-quarter 2025 earnings on Aug. 6, after market close. The company’s ...
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $99.98, which is a 16.7% upside from current levels. In a report issued on July 16, Mizuho Securities also upgraded the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback